Zobrazeno 1 - 10
of 3 089
pro vyhledávání: '"activating mutations"'
Autor:
Yali Wang, Wenbo Zhou, Jianfeng Chen, Jinghong Chen, Peng Deng, Huang Chen, Yichen Sun, Zhaoliang Yu, Diwen Pang, Lizhen Liu, Peili Wang, Jing Han Hong, Bin Tean Teh, Huiqiang Huang, Wenyu Li, Zhengfang Yi, Soon Thye Lim, Yihua Chen, Choon Kiat Ong, Mingyao Liu, Jing Tan
Publikováno v:
MedComm, Vol 4, Iss 4, Pp n/a-n/a (2023)
Abstract Natural killer/T‐cell lymphoma (NKTL) is an uncommon malignancy with poor prognosis and limited therapeutic options. Activating mutations of signal transducer and activator of transcription 3 (STAT3) are frequently found in patients with N
Externí odkaz:
https://doaj.org/article/e18efbf266124b799349530a6ced4565
Publikováno v:
Egyptian Journal of Medical Human Genetics, Vol 23, Iss 1, Pp 1-8 (2022)
Abstract Background Glioblastoma (GBM) is the commonest primary malignant cerebral tumor in adults. Detection of genetic mutations in liquid biopsy is endorsed rapidly throughout several solid neoplasms but still limited in GBM. Our study provides in
Externí odkaz:
https://doaj.org/article/68d43b680dd14f7aaf4bd629d64e02e7
Publikováno v:
Journal of the Egyptian National Cancer Institute, Vol 33, Iss 1, Pp 1-11 (2021)
Abstract Background Breast cancer (BC) is the 2nd most prevalent malignancy worldwide and is the most prevalent cancer among Egyptian women. The number of newly described cancer-associated genes has grown exponentially since the emergence of next-gen
Externí odkaz:
https://doaj.org/article/8d88f3de8cc34bc097eafad6894cf134
Autor:
Mariano Provencio, Josefa Terrasa, Pilar Garrido, Rosario García Campelo, Francisco Aparisi, Pilar Diz, David Aguiar, Carlos García-Giron, Julia Hidalgo, Carlos Aguado, Jorge García González, Emilio Esteban, Lorenzo Gómez-Aldavarí, Teresa Moran, Oscar Juan, Luís Enrique Chara, Juan L. Marti, Rafael López Castro, Ana Laura Ortega, Elia Martínez Moreno, Juan Coves, Ana M. Sánchez Peña, Joaquim Bosch-Barrera, Amparo Sánchez Gastaldo, Natalia Fernández Núñez, Edel del Barco, Manuel Cobo, Dolores Isla, Margarita Majem, Fátima Navarro, Virginia Calvo
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-12 (2021)
Abstract Background AURA study reported 61% objective response rate and progression-free survival of 9.6 months with osimertinib in patients with EGFR/T790M+ non-small cell lung cancer. Due to lack of real-world data, we proposed this study to descri
Externí odkaz:
https://doaj.org/article/8ebc0e8ffdc84091be87e3c5b709643d
Publikováno v:
Cancer Management and Research, Vol Volume 13, Pp 2033-2039 (2021)
Da Peng,1 Dongfeng Shan,2 Chengcheng Dai,1 Jie Li,3 Zifan Wang,1 Ziyi Huang,1 Rui Peng,1 Peng Zhao,4 Xuezhen Ma1 1Department of Oncology, Affiliated Qingdao Central Hospital, Qingdao University, Qingdao, Shandong, People’s Republic of China; 2The A
Externí odkaz:
https://doaj.org/article/3abfe47bcbf54f21bf087dc43e6e28a4
Publikováno v:
Современная онкология, Vol 22, Iss 3, Pp 88-93 (2020)
8090%. The identification of gene mutation profile of non-small cell cancer allows to make a molecular portrait, which plays the crucial role in choosing the targeted therapy with tyrosine kinase inhibitors. The aimis to study the frequency and sp
Externí odkaz:
https://doaj.org/article/fcfdc6aa85ca4280bfec352ae51d9a2d
Autor:
K. I. Zarubina, E. N. Parovichnikova, V. L. Surin, O. S. Pshenichnikova, O. A. Gavrilina, G. A. Isinova, V. V. Troitskaia, A. N. Sokolov, I. V. Gal’tseva, N. M. Kapranov, Iu. O. Davydova, T. N. Obukhova, A. B. Sudarikov, V. G. Savchenko
Publikováno v:
Терапевтический архив, Vol 92, Iss 7, Pp 31-42 (2020)
Issue.The study of activating mutations (NRAS,KRAS,FLT3,JAK2,CRLF2genes) of RAS/RAF/MEK/ERK and JAK/STAT signaling pathways in B-cell acute lymphoblastic leukemia (B-ALL) in adult patients which are included in Russian multicenter clinical trials.
Externí odkaz:
https://doaj.org/article/9c2f567d281a4179aa2fc45866e4cb30
Autor:
Longhua Guo, Zhihong Chen, Chongrui Xu, Xuchao Zhang, Honghong Yan, Jian Su, Jinji Yang, Zhi Xie, Weibang Guo, Feng Li, Yilong Wu, Qing Zhou
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
Abstract Background Intratumoral epidermal growth factor receptor (EGFR) mutational heterogeneity is yet controversial in non-small cell lung cancer (NSCLC) patients. Single-cell analysis provides the genetic profile of single cancer cells and an in-
Externí odkaz:
https://doaj.org/article/009a1ade257e4221a8db5bd4795713ae
Autor:
Claire S. Luke Krishnan, Helen D. Brasch, Josie Patel, Nicholas Bockett, Erin Paterson, Paul F. Davis, Swee T. Tan
Publikováno v:
Frontiers in Surgery, Vol 8 (2021)
Objectives: Arteriovenous malformation (AVM) consists of a nidus with poorly formed low-resistance vessels in place of a functional capillary network. The role of somatic mutations in embryonic stem cells (ESCs) and vascular anomalies and the presenc
Externí odkaz:
https://doaj.org/article/7c03e8df9d17445399fc30ba15710205
Phenotypic transformation as a cause of secondary drug resistance to osimetinib clinical observation
Autor:
L. A. Nelyubina, E. V. Reutova, K. K. Laktionov, D. I. Yudin, D. T. Marinov, E. N. Kozak, V. V. Mochalnikova
Publikováno v:
Медицинский совет, Vol 0, Iss 19, Pp 130-135 (2018)
Targeted therapy is the optimal treatment of patients with advanced EGFR-positive NSCLC. The first- and second-generation EGFR tyrosine kinase inhibitors provide a durable antitumor response in most patients during the year. Due to appearance of T790
Externí odkaz:
https://doaj.org/article/155cc9dbd4534039bf178f1d88bf05bc